Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Virginia for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Virginia only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Virginia (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Celesteann Bremer (NPI 1144213026)

Field	Value
Entity Type	Individual
Organization	Celesteann Bremer
Address	1950 Glenn Mitchell Dr
City	Virginia Beach
State	VA
ZIP	23456
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	August 26, 2005

Payer Source	Total Paid
Medicare	$2.8M
Medicaid	$0

Key Findings

This provider’s activity is centered on oncology infusion and supportive care: the highest-revenue codes are injectable anti-cancer and supportive biologic agents (J9271, J9144, J0897) and the claims mix includes chemotherapy/infusion administration codes (96413, 96401, 96365) and oncology lab testing (85025, 80053, 88185). The presence of many high-volume drug codes and administration CPTs indicates the practice operates as an infusion-centered hematology/oncology practice rather than a purely consultative office.

Revenue is highly concentrated in a small number of high-cost oncology drugs: J9271 (52.8%), J9144 (15.5%), and J0897 (8.5%) together account for 76.8% of this provider's total Medicare revenue, per the precomputed top-3 share. This concentration means most Medicare dollars are driven by a few biologic/immunotherapy agents rather than broad E/M or lab services.

Payer mix is effectively single-payer Medicare: the profile shows Total Medicare revenue of $2.8M and no Medicaid billing on file. Because Medicaid revenue is listed as none, this provider’s reimbursement and volume picture should be interpreted through the lens of Medicare-dominated activity and pricing.

On competitive standing for the top drug, the provider ranks strongly for pembrolizumab billing: J9271 reports 32.6K claims, $43 avg paid/claim, $1.4M revenue (52.8%) and ranks #93 of 1841 providers nationally (95th percentile) with the label “notably above typical national volume for this code.” By contrast, J9144 (10.8K claims, $38, $410.4K; rank #181 of 615, 70th percentile) and J0897 (12.5K claims, $18, $224.6K; rank #772 of 10057, 92th percentile) are more typical participants despite being large revenue contributors.

Several E/M and communication codes are extreme or notable outliers in volume, signaling a substantial office and remote-visit workload alongside infusion care: 99213 shows 1K claims, $63 avg paid/claim, $63.7K revenue and is described as an “extreme outlier, far above typical national volume for this code,” while 99441 (392 claims, $34, $13.3K) is ranked in the 99th percentile and labeled “notably above typical national volume for this code.” The combination of high E/M/telehealth volume with high infusion drug volume suggests the practice blends traditional office-based oncology management with a large infusion throughput.

Onsite laboratory and specimen services appear to be a meaningful operational component: 85025 (3K claims, $8, $24.1K) and 80053 (2.2K claims, $10, $22.2K) sit at the 98th percentile for national peers, and 36415 (2.4K claims, $8, $19.5K) is at the 99th percentile. High counts of routine labs and blood draws support an integrated care model where diagnostics and infusion are coordinated within the practice or its immediate network.

The provider participates in enhanced oncology services as evidenced by M0010 (144 claims, $71 avg paid/claim, $10.2K revenue) ranked #144 of 544 nationally (73th percentile), indicating engagement with the Enhancing Oncology Model payment structure. This participation, together with high infusion drug volumes, aligns the practice with value-based oncology program mechanics while continuing to rely heavily on drug reimbursement.

The NPI has long tenure: enumerated 2005-08-26 (~21 years ago), which combined with the concentrated, high-volume infusion profile suggests an established hematology/oncology practice with stable referral and treatment patterns. Long enrollment plus the observed code mix (high-volume immunotherapies, supportive biologics, administration CPTs, and labs) is consistent with a matured outpatient infusion operation rather than a recently formed or transient billing entity.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

75 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	32,600	$40	$1.4M
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	10,800	$40	$410.4K
J0897	Injection, denosumab, 1 mg	12,480	$20	$224.6K
J1459	Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg	3,240	$40	$119.9K
J9305	Injection, pemetrexed, not otherwise specified, 10 mg	5,840	$10	$81.8K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	1,010	$60	$63.7K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	26,730	$1	$53.5K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	430	$100	$42K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	370	$90	$34.9K
85025	A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a…	3,020	$10	$24.1K

Showing 1–10 of 75

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 75 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Virginia Distribution

Celesteann Bremer — 12 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Virginia

Full comparison — all codes billed, vs. state median

75 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	5	110	12,800	$40	$610.9K
J9144	12	60	8,280	$40	$332.7K
J1459	1	10	3,240	$40	$120.6K
J0897	24	340	2,820	$20	$89.3K
J9305	1	10	3,890	$10	$51.2K
J0881	9	80	10,200	$1	$34.5K
88185	22	60	620	$20	$34.3K
96413	48	230	250	$100	$28.5K
99214	2,916	12,890	140	$80	$21K
J0885	12	40	2,610	$10	$17.3K

Showing 1–10 of 75

Related Providers

Other providers that share a Tax Identification Number (TIN) with Celesteann Bremer, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Virginia Oncology Associates	VA	Hematology & Oncology Physician	$0	$6.2M
Maryland Oncology Hematology P.A.	MD	Hematology & Oncology Physician	$0	$4.6M
Victor Archie	VA	Radiation Oncology Physician	$4M	$0
Julia Schaefer-cutillo	NC	Hematology & Oncology Physician	$4M	$0
Mark Fleming	VA	Hematology & Oncology Physician	$3.9M	$0
Thomas Alberico	VA	Hematology & Oncology Physician	$3.5M	$0
David Kobulnicky	VA	Hematology & Oncology Physician	$3M	$0
Bo Zhao	VA	Hematology & Oncology Physician	$2.6M	$0
Michael Lee	VA	Specialist	$2.3M	$0
Ligeng Tian	VA	Hematology & Oncology Physician	$2.2M	$0

Nearby Providers

Other providers in the same ZIP code as Celesteann Bremer, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Sentara Princess Anne Hospital	VA	General Acute Care Hospital	$0	$37.5M
Yue Zhang	VA	Hematology & Oncology Physician	$1.8M	$1K
Daniel Aruch	VA	Hematology & Oncology Physician	$1.8M	$0
Gauri Radkar	VA	Hematology & Oncology Physician	$863.4K	$0
Jason Shumadine	VA	Radiation Oncology Physician	$669.4K	$0
Princess Anne Ambulatory Surgery Management LLC	VA	Ambulatory Surgical Clinic/Center	$620.2K	$6.2K
William Byrd	VA	Orthopaedic Surgery Physician	$489.9K	$0
Mitchell Miller	VA	Family Medicine Physician	$316.3K	$0
Chad Manke	VA	Orthopaedic Hand Surgery Physician	$304.2K	$0
David Adler	VA	Interventional Cardiology Physician	$256.5K	$0

Celesteann Bremer — Billing Profile & Reimbursement Data

Sign up for Celesteann Bremer — Billing Profile & Reimbursement Data policy alerts

Celesteann Bremer — Billing Profile & Reimbursement Data

Sign up for Celesteann Bremer — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References